Grant Award from GHIT Fund for Development of an Ultrasensitive Urine Test for Tuberculosis
According to the World health Organization (WHO)* 1, up to two million people die from TB each year, making it one of the leading causes of infectious disease death worldwide. Diagnostic tests are typically performed in sputum, a sample type that is difficult to collect and which severely limits the types of TB and patient populations that can be tested. A sensitive, accurate, and accessible non-sputum-based test is urgently needed to reduce the global burden of TB.
The new POC test will measure lipoarabinomannan (LAM), a TB biomarker in urine. Fluxus currently has an ultrasensitive LAM assay prototyped on its benchtop analyzer platform* 2. The GHIT award will fund development towards the launch of the POC instrument and adaptation of the LAM assay to POC test format. The work will be done by Fluxus in partnership with Rapid Research in Diagnostics Development (R2D2) for TB Network, as represented by Heidelberg University Hospital, and Stanford University and Health Care.
This grant enables Fujirebio to further contribute to addressing global health needs and delivering critical improvements in access to healthcare.
*1 WHO. Global Tuberculosis Report 2023, issued on November 7, 2023
*2 https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.974/7987127#google_vignette
The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic's entry into the branded anti-infective segment in the United States, particularly focusing on treatments for urinary tract infections (UTIs). Utility Therapeutics is engaged in developing pharmaceutical products aimed at combating UTIs, a widespread medical condition in the US. The acquisition brings two key assets into Alembic's fold — 'Pivya,' an FDA-approved treatment for uncomplicated UTIs, and 'MEC,' a pipeline product currently under development to address complicated UTI cases. Alembic Pharmaceuticals sees this acquisition as a significant step towards strengthening its presence in the US market with branded specialty products. The deal allows Alembic to market Utility's assets in the US, leveraging the regulatory approvals already in place and continuing the development of promising pipeline therapies. The total consideration for the acquisition is expected to be around $12 million, paid in a staggered manner depending on the achievement of specific milestones. It also includes a provision for profit sharing based on future earnings generated by Utility's products. The transaction does not fall under the related party category, and none of the promoters or group companies have any financial interest in the deal. Completion of the acquisition is anticipated within approximately 30 days, and no additional regulatory approvals are required. This acquisition aligns with Alembic's strategy of expanding its global footprint and diversifying its product offerings in regulated markets like the US. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
9 hours ago
- Yahoo
Asian Market Insights: 3 Stocks That Investors Might Be Undervaluing
As global markets respond to easing trade tensions and positive economic signals, Asian indices have shown resilience, with notable gains in China and Japan. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities amidst the broader market optimism. Name Current Price Fair Value (Est) Discount (Est) T'Way Air (KOSE:A091810) ₩2025.00 ₩4024.62 49.7% Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) CN¥111.64 CN¥222.46 49.8% SIGMAXYZ Holdings (TSE:6088) ¥1221.00 ¥2440.83 50% Shanghai OPM Biosciences (SHSE:688293) CN¥43.21 CN¥85.97 49.7% Prospect Logistics and Industrial Freehold and Leasehold Real Estate Investment Trust (SET:PROSPECT) THB7.20 THB14.35 49.8% Maxscend Microelectronics (SZSE:300782) CN¥69.87 CN¥139.59 49.9% KeePer Technical Laboratory (TSE:6036) ¥3375.00 ¥6748.76 50% Good Will Instrument (TWSE:2423) NT$43.40 NT$86.69 49.9% Forum Engineering (TSE:7088) ¥1195.00 ¥2373.59 49.7% Duk San NeoluxLtd (KOSDAQ:A213420) ₩33600.00 ₩66906.69 49.8% Click here to see the full list of 268 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: Genscript Biotech Corporation is an investment holding company involved in the manufacture and sale of life science research products and services across the United States, Europe, Mainland China, Asia Pacific, and internationally, with a market cap of HK$33.16 billion. Operations: The company's revenue is primarily derived from Life Science Services and Products ($454.95 million), Biologics Development Services ($95.02 million), and Industrial Synthetic Biology Products ($53.69 million). Estimated Discount To Fair Value: 31.1% Genscript Biotech is trading at HK$15.22, significantly below its estimated fair value of HK$22.09, suggesting it may be undervalued based on cash flows. Recent payments totaling US$213.8 million from ProBio bolster its cash reserves, enhancing financial stability and core competencies. While earnings are forecast to grow substantially at 65.8% per year and revenue growth outpaces the Hong Kong market, a low return on equity of 7.1% in three years presents a potential concern for investors seeking high returns. Our expertly prepared growth report on Genscript Biotech implies its future financial outlook may be stronger than recent results. Dive into the specifics of Genscript Biotech here with our thorough financial health report. Overview: Suzhou Nanomicro Technology Co., Ltd. manufactures and supplies spherical, mono-disperse particles for various industries worldwide, with a market cap of CN¥9.13 billion. Operations: The company's revenue segments include the production and distribution of spherical, mono-disperse particles for diverse industrial applications globally. Estimated Discount To Fair Value: 15.5% Suzhou Nanomicro Technology is trading at CN¥22.77, below its estimated fair value of CN¥26.96, indicating potential undervaluation based on cash flows. Earnings are expected to grow significantly at 37.9% per year, outpacing the broader Chinese market's growth rate. Recent financial results show revenue increased to CN¥188.59 million from CN¥154.1 million a year ago, with net income rising to CN¥29.22 million from CN¥16.89 million, supporting its growth trajectory despite a forecasted low return on equity of 11%. The analysis detailed in our Suzhou Nanomicro Technology growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of Suzhou Nanomicro Technology. Overview: SBS Holdings, Inc. offers logistics services both in Japan and internationally, with a market cap of ¥126.90 billion. Operations: The company generates revenue from its Logistics Business, which accounts for ¥429.82 billion, and its Real Estate Business, contributing ¥10.09 billion. Estimated Discount To Fair Value: 35.5% SBS Holdings, trading at ¥3195, is significantly undervalued with a fair value estimate of ¥4956.46 according to discounted cash flow analysis. Despite profit margins declining from 1.9% to 1.3%, earnings are projected to grow at 22.44% annually, surpassing the Japanese market growth rate of 7.5%. However, the dividend yield of 2.66% isn't well covered by free cash flows and debt coverage by operating cash flow remains weak amidst planned strategic acquisitions like Bridgestone Logistics Co., Ltd.'s stock. In light of our recent growth report, it seems possible that SBS Holdings' financial performance will exceed current levels. Click here to discover the nuances of SBS Holdings with our detailed financial health report. Unlock our comprehensive list of 268 Undervalued Asian Stocks Based On Cash Flows by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1548 SHSE:688690 and TSE:2384. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13 hours ago
- Business Wire
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development
BOSTON--(BUSINESS WIRE)-- Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will provide access to its state-of-the-art multi-modal AI foundation models to AstraZeneca. This agreement aims to harness Modella AI's advanced foundation models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca's global oncology portfolio. 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents,' said Jill Stefanelli, CEO of Modella AI. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data driven development and enable the development of new AI agents that can automate complex R&D workflows.' AstraZeneca will leverage Modella AI's platform to enhance its oncology R&D capabilities, with the goal of enhancing clinical development, biomarker discovery, and improving patient outcomes. Both companies will collaborate closely to integrate the models into AstraZeneca's research pipeline, enabling data-driven discovery at increased scale and speed. 'At AstraZeneca, AI is integrated across every aspect of clinical development,' said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' About Modella AI Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: This release may contain forward-looking statements based on current assumptions and forecasts made by Modella AI management. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
